About Alopexx
Alopexx is a Financial Services company based in Cambridge (United States) founded in 2011 by Gerald B Pier, Daniel R Vlock, and Christine De Los Reyes. Investments in healthcare technology sectors are focused on by Alopexx. Its chief executive, as recorded, is Daniel R Vlock. Its focus areas include Investment Industry, Venture Capital Funds, Independent Funds and Conventional VCs.
Company details
Alopexx was established in 2011 as a venture capital firm based in Cambridge, United States. Investments are directed toward healthcare technology sectors by the firm. Operations involve funding startups in areas such as medical devices, diagnostics, and biotech innovations. Leadership is provided by co-founders including Daniel R Vlock as CEO and Christine De Los Reyes as CCO, with a focus on early-stage opportunities in the sector.
- Headquarters Cambridge, United States
- Founders Gerald B Pier, Daniel R Vlock, Christine De Los Reyes
- SectorsFinancial Services
- Email••••••••
- Website alopexx.com
- Social LinkedIn X
People of Alopexx
15 people are tracked at Alopexx (4 in leadership, 10 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Gerald B Pier | Co-Founder | Leadership |
Daniel R Vlock | Co-Founder & CEO | Leadership |
Christine De Los Reyes | Co-Founder & CCO | Leadership |
Thomas T. Thomas | CFO | Leadership |
Richard M Cohen | Board Member | Board & advisors |
Peter J. Werth | Board Member | Board & advisors |
Ann MacDougall | Board Member | Board & advisors |
David Skurnik | Board Member | Board & advisors |
Peter Honig | Board Member | Board & advisors |
William W. Chin | Board Member | Board & advisors |
Douglas Golenbock | Scientific Advisor | Board & advisors |
Martin J. Blaser | Scientific Advisor | Board & advisors |
Johannes Huebner | Scientific Advisor | Board & advisors |
Gail H. Cassell | Board Member | Board & advisors |
James Adams | Consultant | Team |
Complete people profiles for Alopexx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Top companies in Venture Capital Funds
3 companies that operate in the same segment as Alopexx (Venture Capital Funds) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Venture capital firm investing in early-stage tech startups | 1972 | Menlo Park, California, United States | ||||
Venture capital investments and support for entrepreneurs in technology and innovation sectors. | 1911 | Redwood City, California, United States | USD 691.23 K | |||
Accel is recognized as a leading venture capital firm. | 1983 | Palo Alto, California, United States |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Alopexx
Alopexx was founded in 2011.
Alopexx is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Daniel R Vlock is the CEO of Alopexx, as recorded in our data. They have also founded this company.
Alopexx was established in 2011 as a venture capital firm based in Cambridge, United States. Investments are directed toward healthcare technology sectors by the firm. Operations involve funding startups in areas such as medical devices, diagnostics, and biotech innovations. Leadership is provided by co-founders including Daniel R Vlock as CEO and Christine De Los Reyes as CCO, with a focus on early-stage opportunities in the sector.